Japanese pharmaceutical giant Takeda Pharmaceutical (TYO: 4502) has received US approval for Fluzakura (fruquintinib), an oral targeted therapy for colorectal cancer.
The U.S. Food and Drug Administration’s decision targets the treatment of metastatic colorectal cancer (mCRC) in patients who have already tried other options, such as chemotherapy or anti-VEGF therapy.
Fluzacra, an oral and chemotherapy-free option, may offer new hope for patients who:
This article is accessible to registered users. Register for free to read more. Your free trial gives you access to his week of exclusive features, interviews, recaps, and commentary from some of the sharpest minds in pharma and biotech. If you are already a registered user, please log in. If your trial is over, you can subscribe here.
TRY BEFORE YOU BUY
• All the news that moves the pharmaceutical and biotech needle.
• Exclusive features, podcasts, interviews, data analysis and commentary from a global network of life science reporters.
• Receive The Pharma Letter’s daily news bulletins free forever.
become a subscriber
• Free access to industry-leading news, commentary and analysis in pharma and biotech.
• Latest information from clinical trials, conferences, M&A, licensing, financing, regulation, patents and legal affairs, executive appointments, commercial strategy, and financial results.
• Daily roundup of major events in pharma and biotechnology.
• Host monthly in-depth briefings on board appointments and M&A news.
• Choose from cost-effective annual packages or flexible monthly subscriptions.
Thanks for sharing. I read many of your blog posts, cool, your blog is very good.